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Abstract
Background: Non-neutralizing antibodies inducing complement-dependent lysis 
(CDL) and antibody-dependent cell-mediated cytotoxicity (ADCC) activity may con-
tribute to protection against influenza infection. We investigated CDL and ADCC 
responses in healthy adults randomized to receive either non-adjuvanted or AS03-
adjuvanted monovalent A(H1N1)pdm09 vaccine (containing 15 µg/3.75 μg of hemag-
glutinin, respectively) on a 2-dose schedule 21 days apart.
Methods: We conducted an exploratory analysis of a subset of 106 subjects hav-
ing no prior history of A(H1N1)pdm09 infection or seasonal influenza vaccina-
tion enrolled in a previously reported study (NCT00985673). Antibody responses 
against the homologous A/California/7/2009 (H1N1) vaccine strain and a related A/
Brisbane/59/2007 (H1N1) seasonal influenza strain were analyzed up to Day 42.
Results: Baseline seropositivity determined with hemagglutination inhibition (HI), 
CDL and ADCC antibody titers against viral strains was high; A/California/7/2009 
(HI [40.4-48.1%]; CDL [34.6-36.0%]; ADCC [92.1-92.3%]); A/Brisbane/59/2007 (HI 
[73.1-88.9%]; CDL [38.0-42.0%]; ADCC [86.8-97.0%]). CDL seropositivity increased 
following vaccination with both adjuvanted and non-adjuvanted formulations (A/
California/7/2009 [95.9-100%]; A/Brisbane/59/2007 [75.5-79.6%]). At Day 21, in-
creases in CDL and ADCC antibody geometric mean titers against both strains were 
observed for both formulations. After 2 doses of AS03-adjuvanted vaccine, vaccine 
responses of 95.8% (≥9-fold increase from baseline in CDL titers) and 34.3% (≥16-
fold increase from baseline in ADCC titers) were seen against A/California/7/2009; 
and 22.4% and 42.9%, respectively, against A/Brisbane/59/2007. Vaccine responses 
after 2 doses of the non-adjuvanted vaccine were broadly similar.
Conclusions: Broadly comparable non-neutralizing immune responses were ob-
served following vaccination with non-adjuvanted and AS03-adjuvanted A(H1N1)
pdm09 formulations; including activity against a related vaccine strain.
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1  | INTRODUC TION
Following influenza virus infection, a robust immune response is ob-
served involving the generation of both neutralizing and non-neu-
tralizing antibodies.1 Neutralizing antibody responses are directed 
toward the viral hemagglutinin (HA) glycoprotein that mediates virus 
attachment to host cells via sialic acid receptor binding and subse-
quent cell entry. The importance of neutralizing HA-antibodies in 
protection is well established, and influenza vaccines are developed 
and assessed primarily by their ability to induce hemagglutination 
inhibition (HI) as a surrogate for neutralizing antibodies.2,3 However, 
most conventional HA-specific neutralizing antibodies target epi-
topes of the HA globular head that, while immunodominant, are 
subject to substantial antigenic drift and are typically strain-specific; 
hence the need for annual updating of the composition of the sea-
sonal influenza vaccines so as to target and induce protective neu-
tralizing antibodies to the anticipated predominant seasonal strains.3
Non-neutralizing antibodies to influenza are also generated 
following infection and provide additional protection via a range 
of mechanisms including complement-dependent lysis (CDL) and 
antibody-dependent cell-mediated cytotoxicity (ADCC).4-11 Such 
non-neutralizing antibodies can recognize and bind a range of viral 
epitopes expressed by influenza virus on the surface of infected cells 
with subsequent complement activation or direct cell lysis by natural 
killer (NK) cells, monocytes, and macrophages in conjunction with 
antiviral cytokine release.6,11 A potential benefit of such non-neu-
tralizing antibodies is their recognition of epitopes within the HA 
globular head and also of more highly conserved epitopes (eg, in the 
HA stalk domain) than those recognized by neutralizing antibodies, 
so offering a broader cross-reactive protection.5,12 These non-neu-
tralizing antibodies include those directed against internal proteins 
such as nucleoprotein and matrix 1 protein to which ADCC antibody 
responses are observed following clinical infection or influenza vac-
cination.9,13 These aspects are of particular relevance to pandemic 
influenza and associated vaccine development, where virus genomic 
reassortment events result in novel strains with novel viral epitopes 
in their more variable antigenic domains.10,11,14 In this respect, the 
role of CDL and ADCC antibodies in response to influenza infection 
or following vaccination is of considerable interest, with a number of 
reports in recent years.7,9,13,15-18 However, data from vaccine clinical 
studies are more limited.
Previously, we reported on a randomized controlled trial 
(NCT00985673) evaluating immunogenicity and safety of a mon-
ovalent A(H1N1)pdm09 pandemic influenza vaccine given with or 
without AS03 adjuvant.19 Use of adjuvants such as AS03 is an im-
portant consideration in pandemic vaccine development as it pro-
vides an antigen sparing component to vaccine composition, which 
may be relevant when antigen availability to novel strains is limited. 
In that study, robust HI antibody responses were observed with both 
the non-adjuvanted (15 µg of hemagglutinin) and AS03-adjuvanted 
vaccine formulations (3.75 µg of hemagglutinin); where the differ-
ences in hemagglutinin content in these different formulations rep-
resent such an antigen sparing effect.19 To investigate the effect of 
these vaccine formulations on non-neutralizing antibody responses, 
we performed an exploratory evaluation and analysis of CDL and 
ADCC antibody responses, using sera collected in a sub-population 
of this study cohort. The aims were to characterize non-neutralizing 
antibody immunogenicity against the homologous A(H1N1)pdm09 
vaccine strain (A/California/7/2009) and also against a related sea-
sonal influenza strain; A/Brisbane/59/2007(H1N1) representative of 
a previously circulating seasonal H1N1 subtype (which in the con-
text of the present analysis we consider this to be a heterologous 
vaccine strain).
2  | MATERIAL S AND METHODS
2.1 | Study design and study population
This was an exploratory analysis of a sub-population of a previ-
ously reported randomized, observer-blind, controlled clinical trial 
(NCT00985673) conducted in the United States and Canada be-
tween October 2009 and December 2010. The study design, inclu-
sion criteria, and primary objectives (immunogenicity and safety) 
have previously been published.19 Participants were healthy adults 
19 to 40 years of age, excluding subjects with any prior history 
of A(H1N1)pdm09 influenza vaccination or physician-confirmed 
A(H1N1)pdm09 infection, and those with a history of previous sea-
sonal influenza vaccination.19 The study was conducted in accord-
ance with Good Clinical Practice and the Declaration of Helsinki. 
All study-related documents were approved by the appropriate 
Institutional Review Boards of participating Centres; and written in-
formed consent was obtained from all subjects prior to enrollment. 
Anonymized individual participant data and study documents can be 
requested for further research from www.clini calst udyda tareq uest.
com.
The current analysis involved a subset of those participants 
from this parent study (corresponding to groups E and F) who were 
randomized to receive non-adjuvanted or AS03-adjuvanted for-
mulations, respectively, of a A(H1N1)pdm09 pandemic influenza 
vaccine.19 The A(H1N1)pdm09 pandemic influenza vaccine is a mon-
ovalent, inactivated, split-virion antigen either in non-adjuvanted 
form (with 15 µg of hemagglutinin) or as an AS03-adjuvanted for-
mulation (Arepanrix, GSK, Belgium); with 3.75 µg of hemagglutinin,19 
and which contains DL-α-tocopherol and squalene in an oil-in-water 
emulsion.20
Subjects in this exploratory analysis were randomly drawn from 
the according-to-protocol (ATP) cohort in each group, with subject 
K E Y W O R D S
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selection based on available blood samples for additional testing 
for non-neutralizing antibody responses. Subjects received either 
non-adjuvanted or AS03-adjuvanted formulations on Days 0 and 21 
administered in the deltoid muscle; no other vaccines were adminis-
tered during this time-frame (and so for the purposes of the present 
analysis received only the monovalent vaccine).19
Blood samples were collected on Day 0 (pre-vaccination) and 
on Days 21 and 42 (ie, 21 days after each vaccine dose). All sam-
ples were coded with a unique identification number, aliquoted, and 
stored at −80°C until analysis.
2.2 | Immunogenicity assays
HI antibody titers against the homologous H1N1pdm09 vaccine 
strain (inactivated A/California/7/2009) and the seasonal influenza 
strain (A/Brisbane/59/2007) were measured (in duplicate) as previ-
ously reported in the primary study using a validated assay cut-off 
value (≥1:10).19
CDL and ADCC assays were performed at the University of 
Massachusetts Medical School (UMMS). The principles and tech-
nical details of these chromium-release assays have previously 
been described.7,15 For the CDL assay, A549 cells (human lung ep-
ithelial cell line; ATCC CCL-185) were infected with egg-derived A/
California/7/09 (H1N1)pdm09 and A/Brisbane/59/2007 virus strains 
incubated overnight then labeled with 51chromium for 1-hour. These 
infected target cells were then seeded in 96-well plates (at 2000 
cells/well) to which 3-fold serial dilutions (1:32-1776) of heat-inac-
tivated sera from study subjects were added to appropriate wells 
(in replicates of three) and incubated in the presence of comple-
ment (Low-Tox Guinea Pig Complement, Cedarlane Laboratories, 
Burlington, North Carolina). RENEX detergent or RPMI 1640 me-
dium was added to maximum release and minimum release wells, 
respectively. Plates were centrifuged at 250 g for 5 minutes, pelleted 
cells incubated for 2-hours, and then supernatants harvested from 
each well and counted in a gamma counter as counts per minute 
(CPM). In all assays, serum from an adult with CDL antibodies against 
seasonal A(H1N1) was used as a positive control. The percentage 
specific immune lysis (%SIL) of infected A549 cells was then calcu-
lated at each serum dilution as follows: %SIL = (CPM of experimental 
release−average CPM of complement minimum release)/(average 
CPM of maximum release−average CPM of complement minimum 
release)*100. The CDL serum antibody endpoint titer was defined as 
the highest serum dilution at which ≥50% peak SIL of the sample was 
observed. In previous studies, we have used different thresholds in-
cluding ≥15%,7 and also ≥50%,6 as in the present study. Based upon 
this ≥50% peak SIL threshold, the assay cut-off was established as 
32.0 (first assay dilution [1/DIL]), and subjects with a titer <32.0 1/
DIL were considered seronegative.
For the ADCC assay, A549 cells were infected with A/
California/7/09 (H1N1)pdm09 and A/Brisbane/59/2007 virus 
strains, then 51chromium-labeled and plated in a similar manner as 
in the CDL assay. Heat-inactivated sera from study subjects were 
added in 4-fold serial dilutions (1:32-1:32 768) in the presence of 
enriched NK cells derived and sourced from peripheral blood mono-
nuclear cell samples obtained from nine healthy subjects >18 years 
old at UMMS (with informed consent and Institutional Review Board 
approval). NK cells were added in an effector-to-target cell ratio of 
5:1. RENEX detergent or RPMI medium was then added and super-
natants subsequently harvested in a similar manner as for the CDL 
assay. All sera were tested in replicates of three and serum from an 
adult with ADCC antibodies against seasonal A(H1N1) used as a pos-
itive control. The %SIL of infected A549 cells was then calculated at 
each serum dilution as (% lysis of sample−% lysis of NK cells alone). 
Calculation of % lysis of sample or of NK cells alone was calculated 
as follows: % lysis of sample = (average CPM of experimental re-
lease−average CPM of minimum release)/(average CPM of maxi-
mum release−average CPM of minimum release)*100; % lysis of NK 
cells = (average CPM of NK cell release−average CPM of minimum 
release)/(average CPM of maximum release−average CPM of mini-
mum release)*100. The ADCC antibody endpoint titer was defined 
in a similar manner as for the CDL assay, that is, the highest serum 
dilution at which ≥50% peak SIL of the sample was observed, with a 
similar cut-off value (32.0 1/DIL) used.
2.3 | Immunogenicity assessments
HI seropositivity status was assessed at baseline (Day 0) and on Day 
42; seropositivity rate was defined as the percentage of subjects 
with HI titer equal to or above the assay cut-off value (≥10), con-
sistent with the approach used in the parent study and other stud-
ies evaluating HI immunogenicity in response to the H1N1pdm09 
vaccine.19,21
For both CDL and ADCC assays, we evaluated seropositivity, 
geometric mean titer (GMT), vaccine response (VR), and mean geo-
metric increase (MGI). Subjects were considered seropositive for 
CDL or ADCC antibodies if their antibody titer was equal to or above 
the assay cut-off (≥32.0 1/DIL). For GMT calculations, titers were 
log10 transformed and then calculations performed using the antilog 
of the mean of the log10 titer transformations. For CDL, titers <32.0 
1/DIL were assigned a value of 10.7 1/DIL (to account for the 3-fold 
dilution), and for endpoint titers above the maximum assay readout 
value of the serum dilutions tested (>7776 1/DIL), a maximal titer 
of 23 328 1/DIL was assigned. For ADCC, titers <32.0 1/DIL were 
assigned a value of 8.0 1/DIL (to account for the 4-fold dilution); 
endpoint titers above the maximum assay readout (>32 768 1/DIL) 
were assigned a maximal titer of 131 072 1/DIL.
No standardized VR criteria exist, and to account for this uncer-
tainty, we used two exploratory levels of response thresholds to deter-
mine VR, and applied both to assess VR at Day 21 and Day 42. For the 
CDL assay, VR was defined as the proportion of subjects who showed 
a 3-fold or 9-fold increase in the post-vaccination reciprocal titer from 
baseline. For those subjects with baseline titers of <32.0 1/DIL (con-
sidered seronegative at baseline), post-vaccination reciprocal titers of 
≥96.0 1/DIL or ≥288.0 1/DIL were required to meet these 3-fold and 
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9-fold thresholds, respectively. For the ADCC assay, a similar approach 
was adopted (but using subsequent 4-fold or 16-fold increases from 
baseline in post-vaccination reciprocal titers; subjects seronegative 
at Day 0 required post-vaccination reciprocal titers of ≥128 1/DIL or 
≥512.0 1/DIL to meet these thresholds). MGI was defined as the geo-
metric mean fold rise in GMTs at Day 21/Day 42 relative to Day 0.
2.4 | Data analysis
Descriptive analyses were performed for all data and summarized 
for each time-point for each study group (ie, subjects receiving ei-
ther the non-adjuvanted or AS03-adjuvanted vaccine). GMTs, MGIs, 
and the percentage of seropositive subjects, and VRs (with 95% 
confidence intervals [CIs]) were each tabulated. Reverse cumulative 
distribution curves at Day 42 were also generated. For each of the 
CDL and ADCC datasets, differences between groups (ie, AS03-
adjuvanted vaccine group minus non-adjuvanted vaccine group) in 
the percentage of subjects with a VR at Day 42 were calculated. 
The GMT ratio at Day 42 was analyzed via analysis of covariance 
(ANCOVA) models on the log10 transformed titers, including the vac-
cine group as a fixed effect and age and the baseline value (Day 0) 
as covariates. The 95% CI for the adjusted-GMT ratio was obtained 
by exponential-transformation of 95% CIs for the mean of log-trans-
formed titer. Correlations between HI, CDL, and ADCC antibody 
titers were evaluated using linear regression and by calculating the 
correlation coefficient (r) values. Correlation scores were considered 
as follows: <0.63 as poor, 0.63-0.77 as fair, 0.77-0.86 as good, and 
>0.86 as excellent.
All statistical analyses were performed using the SAS software 
(SAS Institute Inc, NC, United States).
3  | RESULTS
From the original ATP cohort from the primary study, 106 subjects 
were included in this exploratory analysis (accounting for approxi-
mately 50% of eligible participants); 52 receiving the non-adjuvanted 
F I G U R E  1   Study flow. From the 
original according-to-protocol cohort 
from the primary study, 106 subjects 
were included: 52 receiving the non-
adjuvanted vaccine and 54 receiving 
the AS03-adjuvanted vaccine. ADCC, 
antibody-dependent cell-mediated 
cytotoxicity; ATP, according-to-protocol; 
CDL, complement-dependent lysis; 
HA, hemagglutinin; HI, hemagglutinin 
inhibition; n, number of subjects with 
available results for all three antibody 
responses (HI, CDL and ADCC); N, total 
number of subjects in the non-adjuvanted 
or AS03-adjuvanted vaccine group; TVC, 
total vaccinated cohort
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vaccine and 54 receiving the AS03-adjuvanted vaccine. Study flow 
and number of subjects assayed at study time-points are shown in 
Figure 1. Cohort demographics are presented in Table 1. Baseline HI 
antibody titers indicated that 40.4-48.1% of subjects were seroposi-
tive for the A/California/7/2009 strain and 73.1-88.9% for the A/
Brisbane/59/2007 strain (Table 1 and Figure 2).
3.1 | Immunogenicity based on CDL antibody assay
Prior to vaccination, baseline seropositivity for CDL antibodies for 
A/California/7/2009 in each study group ranged between 34.6% 
and 36.0%, and between 38.0% and 42.0% for A/Brisbane/59/2007 
(Table 2 and Figure 2). Twenty-one days after vaccination with 
the first dose of non-adjuvanted vaccine, seropositivity increased 
to 95.8% against A/California/7/2009 and 67.3% against A/
Brisbane/59/2007; all subjects receiving the AS03-adjuvanted vac-
cine were seropositive against A/California/7/2009 and 76.0% sero-
positive against A/Brisbane/59/2007. At Day 42, the high proportion 
of subjects seropositive against A/California/7/2009 was main-
tained for both vaccine formulations, with an increase in the propor-
tion of participants seropositive against the A/Brisbane/59/2007 
strain also observed for both vaccine groups (Table 2 and Figure 2).
Baseline CDL antibody GMTs in each study group ranged be-
tween 24.5 and 26.7 for A/California/7/2009 and between 30.1 
and 31.8 for A/Brisbane/59/2007. Strong increases in GMTs were 
observed at 21 days post-vaccination for either vaccine (Table 2 
and Figure 3). The highest GMTs were observed against A/
California/7/2009, with titers increasing with each vaccine dose; 
GMTs against the A/Brisbane/59/2007 strain also increased after 
each vaccine dose (Table 2). Reverse cumulative distribution curves 
at Day 42 demonstrating CDL and ADCC antibody responses against 
the homologous A/California/7/2009 vaccine strain and against A/
Brisbane/59/2007 are shown in Figure S1.
CDL antibody VRs are shown in Figure 4 and Table S1. The great 
majority of subjects receiving either vaccine showed responses to 
the homologous A/California/7/2009 virus antigen after the first 
dose (Day 21) with over 90% of subjects in the non-adjuvanted 
vaccine group and 100% of those receiving the AS03-adjuvanted 
vaccine showing a 3-fold increase in GMTs from baseline; the per-
centage of subjects with a 9-fold increase in CDL titers from baseline 
was also high. These responses were maintained after the second 
dose (Day 42), where 9-fold increases were observed in 85.7% of 
subjects in the non-adjuvanted vaccine group and 95.8% of those re-
ceiving the AS03-adjuvanted vaccine. For the A/Brisbane/59/2007 
strain, VRs at Day 42, as assessed using the 9-fold increase thresh-
old, were observed in 20.4% (non-adjuvanted vaccine group) and 
22.4% (AS03-adjuvanted vaccine) of subjects. For both strains, VRs 
were seen in a higher proportion of subjects seronegative at baseline 
than in seropositive subjects (Figure 4 and Table S1).
Differences in VRs between the AS03-adjuvanted vaccine and 
the non-adjuvanted groups are presented in Table S2 and adjusted 
GMTs, MGI and adjusted-GMT ratio in Table S3. Between-group dif-
ferences in CDL VRs and adjusted-GMT ratios against either vaccine 
strain were inconsistent, and with overlapping CIs in between-group 
comparisons.
We evaluated correlations between CDL and HI antibody titers 
at Day 42, in both vaccine groups and in the total exploratory anal-
ysis cohort (Table S4 and Figure S2). Overall, there was fair linear 
correlation between HI and CDL titers against A/California/7/2009, 
with correlation coefficient (r) values of 0.68-0.69 (Figure S2). 
Correlations between HI and CDL antibody titers against A/
Brisbane/59/2007 were strong on initial analysis but after removal 
of an outlier patient the adjusted correlation was very poor, with r 
between 0.14 and 0.26 (Table S4).
3.2 | Immunogenicity based on ADCC 
antibody assay
A high proportion of subjects in either study group were seroposi-
tive for ADCC antibodies against both vaccine strains at baseline, 
Patient characteristics
Non-adjuvanted vaccine
N = 52
AS03-adjuvanted vaccine
N = 54
Age, years
Mean (SD) 29.5 (6.3) 28.9 (6.6)
Range 19-40 19-40
Gender, n (%)
Female 36 (69.2%) 32 (59.3%)
Male 16 (30.8%) 22 (40.7%)
Evidence of previous natural infectiona , n (%)
A/California/7/2009 strain 21 (40.4%) 26 (48.1%)
A/Brisbane/59/2007 strain 38 (73.1%) 48 (88.9%)
Abbreviations: AS03, Adjuvant System containing DL-α-tocopherol and squalene in an oil-in-water 
emulsion; n, number of subjects with available results; N, total number of subjects in the non-
adjuvanted or AS03-adjuvanted vaccine groups; SD, standard deviation.
aBased upon baseline hemagglutination inhibiting antibody measurements (titers ≥ 10 at Day 0). 
TA B L E  1   Sociodemographic 
parameters for present analysis according-
to-protocol cohort for immunogenicity
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where seropositivity for A/California/7/2009 ranged between 
92.1% and 92.3% and for A/Brisbane/59/2007 between 86.8% and 
97.0% (Figure 2 and Table 2). At Day 42, 21 days after a second dose, 
all subjects receiving the non-adjuvanted vaccine, and 94.7% of the 
AS03-adjuvanted vaccine group were seropositive for ADCC anti-
bodies against A/California/7/2009. For the A/Brisbane/59/2007 
strain, seropositivity remained high following vaccination in subjects 
in the non-adjuvanted group, while seropositivity increased in sub-
jects receiving the AS03-adjuvanted vaccine after the first dose (to 
97.4%) with no subsequent change with the second dose.
ADCC antibody GMTs at baseline ranged from 970.4 to 1202.5 
against A/California/7/2009 and from 758.3 to 1185.9 against A/
Brisbane/59/2007. GMTs against A/California/7/2009 increased 
after each vaccine dose in both study groups; for A/Brisbane/59/2007 
GMTs rose substantially after dose 1 then remained stable (AS03-
adjuvanted vaccine group) or declined (non-adjuvanted group) 
(Table 2 and Figure 3). In contrast to GMTs observed with the CDL 
assay, GMT levels against A/Brisbane/59/2007 were of a broadly 
comparable level to those observed for A/California/7/2009 
(Table 2 and Figure 3).
F I G U R E  2   Baseline seropositivity to hemagglutination inhibition (HI), complement-dependent lysis (CDL), and antibody-dependent cell-
mediated cytotoxicity (ADCC) antibodies against A/California/7/2009 and A/Brisbane/59/2007 strains at baseline (Day 0) and Day 42. D, 
Day
     |  7FRIEL Et aL.
When evaluating ADCC responses, lower VRs against A/
California/7/2009 virus antigen were seen compared to A/
Brisbane/59/2007. For A/California/7/2009, the proportion of par-
ticipants with a 16-fold increase in ADCC titers from baseline was 
<40% in either group at Day 42; VRs against the A/Brisbane/59/2007 
strain were marginally higher in both vaccine groups (41.9-42.9) at 
this time-point (Figure 4 and Table S1).
Similar to our CDL data, between-group differences in VRs and 
adjusted-GMT ratios for ADCC antibodies against either strain 
were inconsistent (Tables S2 and S3). Correlations between ADCC 
and HI antibody titers against A/California/7/2009 and against A/
Brisbane/59/2007 at Day 42 were poor (Table S4). In addition, correla-
tions between CDL and ADCC titers were also poor for either strain.
4  | DISCUSSION
We evaluated CDL and ADCC antibody responses after immuni-
zation with either non-adjuvanted or AS03-adjuvanted pandemic 
A(H1N1)pdm09 vaccine in a subset of participants from a previously 
reported clinical trial,19 measuring antibody GMTs and VRs against 
the homologous (A/California/7/2009) strain and against a seasonal 
influenza heterologous strain (A/Brisbane/59/2007).
In this study cohort, a high proportion of subjects had HI an-
tibody baseline titers to A/California/7/2009 (40-48%) and A/
Brisbane/59/2007 (73-89%). We found that the numbers of sub-
jects with detectable baseline CDL and ADCC antibodies to these 
A/California/7/2009 and A/Brisbane/59/2007 vaccine strains 
were also high. As measured via CDL antibodies, 35-36% were se-
ropositive against A/California/7/2009 and 38-42% against A/
Brisbane/59/2007. Baseline seropositivity for ADCC titers was sub-
stantially higher, with 92% of participants seropositive for the A/
California/7/2009 strain and 87-97% for A/Brisbane/59/2007.
As study participants had no prior history of trivalent inac-
tivated influenza vaccine immunization or pandemic A(H1N1)
pdm09 infection, such high pre-vaccination seropositivity may re-
flect previous exposure (ie, subclinical natural infection to these 
vaccine strains). While past exposure to seasonal influenza may 
be expected, and so may explain the high seropositivity against 
A/Brisbane/59/2007, the high baseline seropositivity for the 
pandemic A/California/7/2009 strain is perhaps more surprising 
(as previous pandemic infection, although possible, may be con-
sidered less likely). A plausible explanation is that these pre-vac-
cination levels represent pre-existing cross-reactive A(H1N1)
pdm09-specific ADCC antibodies (and to a lesser extent CDL an-
tibodies) induced by previous seasonal influenza infection, rather 
TA B L E  2   Complement-dependent lysis (CDL) and antibody-dependent cell-mediated cytotoxicity (ADCC) antibody responses 
(seropositivity and geometric mean titers [GMTs]) to A/California/7/2009 and A/Brisbane/59/2007 strains (according-to-protocol cohort for 
immunogenicity)
Non-adjuvanted vaccine (N = 52) AS03-adjuvanted vaccine (N = 54)
n/Na 
Seropositive % 
(95% CIs) GMT (95% CIs) n/Na 
Seropositive % 
(95% CIs) GMT (95% CIs)
CDL antibodies
A/California/7/2009 strain
Day 0 18/50 36.0 (22.9-50.8) 26.7 (17.9-40.0) 18/52 34.6 (22.0-49.1) 24.5 (17.1-35.1)
Day 21 46/48 95.8 (85.7-99.5) 1331.4 (788.7-2247.8) 51/51 100 (93.0-100) 2940.6 (2067.2-4182.8)
Day 42 47/49 95.9 (86.0-99.5) 1651.9 (1007.9-2707.6) 48/48 100 (92.6-100) 5421.9 (3951.3-7439.9)
A/Brisbane/59/2007 strain
Day 0 19/50 38.0 (24.7-52.8) 30.1 (19.9-45.4) 21/50 42.0 (28.2-56.8) 31.8 (20.7-49.1)
Day 21 33/49 67.3 (52.5-80.1) 72.1 (44.9-115.6) 38/50 76.0 (61.8-86.9) 160.1 (93.0-275.8)
Day 42 37/49 75.5 (61.1-86.7) 127.2 (78.2-206.9) 39/49 79.6 (65.7-89.8) 179.1 (106.7-300.7)
ADCC antibodies
A/California/7/2009 strain
Day 0 36/39 92.3 (79.1-98.4) 1202.5 (568.3-2544.2) 35/38 92.1 (78.6-98.3) 970.4 (499.0-1887.1)
Day 21 35/38 92.1 (78.6-98.3) 6243.8 (2605.8-14 961.1) 36/39 92.3 (79.1-98.4) 6991.4 (2837.4-17 226.8)
Day 42 40/40 100 (91.2-100) 12 403.6 (6321.2-24 338.5) 36/38 94.7 (82.3-99.4) 9533.0 (4180.0-21 741.4)
A/Brisbane/59/2007 strain
Day 0 32/33 97.0 (84.2-99.9) 1185.9 (598.1-2351.1) 33/38 86.8 (71.9-95.6) 758.3 (327.1-1757.9)
Day 21 28/29 96.6 (82.2-99.9) 8994.1 (3856.5-20 976.1) 37/38 97.4 (86.2-99.9) 9978.7 (4789.7-20 789.4)
Day 42 30/32 93.8 (79.2-99.2) 6876.0 (2718.2-17 393.7) 36/37 97.3 (85.8-99.9) 9822.0 (4530.1-21 295.8)
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; AS03, Adjuvant System containing DL-α-tocopherol and squalene in an oil-in-
water emulsion; CDL, Complement-dependent lysis; CIs, confidence intervals; GMT, geometric mean titer.
an, number of (seropositive) subjects with antibody titer ≥ 32.0 1/dilution on CDL or ADCC assay; N, number of subjects with available results. 
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than due to previous pandemic influenza infection. This is sup-
ported by data from previous studies where healthy adults had 
high levels of ADCC antibodies to pandemic A(H1N1) and A(H5N1) 
and A(H7N9) virus strains, even though it was considered unlikely 
that previous clinical exposure had occurred.9,13,15,16 In this con-
text, although we observed lower baseline with the CDL assay, this 
is consistent with previous data in which CDL antibodies against 
pandemic strains were detected in only a fraction of subjects with 
high ADDC antibody titers,7,15 although different assay sensitivi-
ties may also have influenced our results.
Immunization with either unadjuvanted or AS03-adjuvanted 
A(H1N1)pdm09 influenza vaccine was followed by increasing se-
ropositivity rates and substantial increases in GMTs (for both CDL 
and ADCC antibodies) against both A/California/7/2009 and A/
F I G U R E  3   CDL and ADCC antibody geometric mean titers (GMTs) against A/California/7/2009 and A/Brisbane/59/2007 strains at 
baseline and Days 21 and 42. Upper panel represents GMTs as measured by CDL assay and lower panel by ADCC assay. ADCC, antibody-
dependent cell-mediated cytotoxicity; CDL, complement-dependent lysis; D, Day; GMT, geometric mean titer
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Brisbane/59/2007 strains. Only relatively minor (and non-signifi-
cant) differences in the kinetics and magnitude of responses were 
observed between the different vaccine formulations.
For CDL antibodies, GMTs against A/California/7/2009 and A/
Brisbane/59/2007 following both the first and the second vaccine dose 
were higher in the AS03-adjuvanted vaccine group than in non-adju-
vanted vaccine recipients. In addition, the kinetics of the CDL antibody 
response against A/California/7/2009 shows that while only modest 
increases in GMT were seen following a second dose of non-adjuvanted 
vaccine, GMTs markedly increased following dose 2 of the AS03-
adjuvanted vaccine. ADCC antibody GMTs against A/California/7/2009 
increased after each vaccine dose in both study groups. In contrast, while 
notable increases in GMTs for the heterologous A/Brisbane/59/2007 
strain were observed following the first vaccine dose of either vaccine, 
a subsequent second dose resulted in little change. The more strik-
ing differences were observed for the VRs observed against differ-
ent vaccine strains and as measured by different assays, with few 
differences between non-adjuvanted and AS03-adjuvanted vaccine 
groups. For the CDL assay, VRs were substantially higher against the 
homologous A/California/7/2009 strain than for the heterologous A/
Brisbane/59/2007 strain. In contrast, for ADCC responses, VRs were 
relatively similar against either strain. Looking across these response 
data, we see that VRs against the A/California/7/2009 strain were far 
higher when evaluating CDL antibodies than those responses seen with 
ADCC antibodies; in contrast, for the A/Brisbane/59/2007 strain, the 
higher responses were observed when using the ADCC assay. We have 
no obvious explanation for this, and in part it may reflect the uncer-
tainty around the response thresholds we used.
F I G U R E  4   Vaccine responses in subjects receiving non-adjuvanted and AS03-adjuvanted vaccines against A/California/7/2009 and A/
Brisbane/59/2007 strains at Day 21 and Day 42. Presented here are higher vaccine response thresholds; defined as a 9-fold increase from 
baseline (Day 0) at Day 21 or Day 42 for CDL antibodies (and as a 16-fold increase for ADCC antibodies); see also data in Table S2. ADCC, 
antibody-dependent cell-mediated cytotoxicity; CDL, complement-dependent lysis; D, Day
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The generally comparable immunogenicity we observed with the 
AS03-adjuvanted vaccine in generating robust CDL and ADCC re-
sponses is consistent with that seen for HI responses in the primary 
study,19 as well as that from other studies evaluating conventional HI 
immunogenicity of AS03-adjuvanted pandemic A(H1N1)pdm09 vac-
cines. In the latter, lower HA antigen induces comparable HI antibody 
responses to conventional non-adjuvanted formulations with higher 
HA content.21,22 Our results are also consistent with other recent data 
on AS03-adjuvanted H1N1pdm09 vaccine, where robust ADCC re-
sponses were observed in subjects regardless of baseline HI seroposi-
tivity.17,18 They are also consistent with studies using other influenzas 
vaccine, including a recent study demonstrating ADCC responses to 
quadrivalent and MF-59 adjuvanted vaccines in older adults.23
The present study has some limitations. While we have evalu-
ated responses at a group level, we have not accounted for individual 
subject responses, and the impact that baseline seropositivity (in the 
context of primed and unprimed subjects) may have had in subse-
quent CDL and ADCC antibody responses. Data suggest that while 
post-vaccination titers for HI and ADCC antibodies are broadly com-
parable in primed and unprimed subjects, the vaccine responses in 
terms of foldincreases from baseline may differ; it has been reported 
that higher fold increases in HI and ADCC titers in response to AS03-
adjuvanted A(H1N1)pdm09 vaccine are seen in unprimed subjects.17 
The CDL and ADCC assays we used, while developed and qualified in 
a similar manner as in previous studies,7,13,15 were exploratory, as were 
our vaccine response thresholds. For ADCC responses, NK cells were 
sourced from multiple healthy donors, and donor variation in NK cells 
may have influenced our ADCC responses. Another limitation is that 
we cannot identify the viral epitopes which determine the pre-exist-
ing CDL and ADCC antibody titers and subsequent responses.
5  | CONCLUSIONS
Cross-reactive CDL and ADCC antibodies may constitute crucial com-
ponents of immune responses and provide some level of protection 
against existing and emerging pandemic influenza viruses.24 Their 
role in providing protection against seasonal influenza is increasingly 
recognized, as is the need to more fully consider non-neutralizing an-
tibody responses in vaccine development for a better characterization 
of the immune response of next-generation vaccine candidates.25
Our data support these views and provide further evidence that 
ADCC and CDL assays should be an important consideration in vaccine 
development and evaluation and for the design of future, more cross-re-
active vaccines (eg, universal vaccine). The possibility that antigens in 
the vaccine such as nucleoprotein and matrix 1 protein might contrib-
ute to cross-reactive, non-neutralizing immune responses cannot be 
ruled out. Determining the levels of these antigens in the vaccine would 
be important to investigate this. Non-neutralizing immune responses 
following vaccination with non-adjuvanted and AS03-adjuvanted 
formulations were observed; responses were broadly comparable 
with either vaccine formulation. Seropositivity, GMTs and vaccine re-
sponses for CDL antibodies were greater against the homologous A/
California/7/2009 strain than for the A/Brisbane/59/2007 strain, but 
there was substantial evidence of cross-reactivity. For ADCC antibod-
ies, more variability was observed, and there were higher VRs toward 
the heterologous A/Brisbane/59/2007 strain. Reduced HA antigen 
content (antigen sparing) in the AS03-adjuvanted formulation did not 
impact upon the magnitude or kinetics of these responses.
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